bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials
Authors: Streck Joanna M. , Lee Ju-Whei , Walter Angela Wangari. , Rosen Rachel L. , Gareen Ilana F. , Kircher Sheetal Mehta. , Herman Benjamin A. , Carlos Ruth C. , Kumar Shaji , Mayer Ingrid A. , Saba Nabil F. , Fenske Timothy S. , Neal Joel W. , Atkins Michael B. , Hodi F Stephen. , Kyriakopoulos Christos E. , Tempany Clare , Shanafelt Tait D. , Wagner Lynne I. , Land Stephanie R. , Park Elyse R. , Ostroff Jamie S.
Published: September 2024

Abstract
Background: While cigarette smoking has declined among the US general population, sale and use of non-cigarette alternative tobacco products (ATPs; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known about ATP use patterns in cancer survivors enrolled in clinical trials. We investigated prevalence of tobacco product use, and factors associated with past 30-day use, among cancer patients in national trials.
Methods: Cancer survivors (N=756) enrolled in 9 ECOG-ACRIN clinical trials (2017-2021) completed a modified Cancer Patient Tobacco Use Questionnaire (C-TUQ) which assessed baseline cigarette and ATP use since cancer diagnosis and in the past 30-days (30d).
Results: Patients were on average 59 years old, 70% male, and the mean time since cancer diagnosis was 26 months. Since diagnosis, cigarettes (21%) were the most common tobacco product used, followed by smokeless tobacco use (5%), cigars (4%), and e-cigarettes (2%). In the past 30d, 12% of patients reported smoking cigarettes, 4% cigars, 4% using smokeless tobacco, and 2% e-cigarettes. Since cancer diagnosis, 5.5% of the sample reported multiple tobacco product use, and 3.0% reported multiple product use in the past 30d. Males (vs. females) (OR 4.33; p=0<.01) and individuals not living with another person who smokes (vs. living with) (OR 8.07; p=0<.01) were more likely to use ATPs only vs. cigarettes only in the past 30d.
Conclusions: Among cancer patients, cigarettes were the most prevalent tobacco product reported.
Impact: Regardless, ATPs and multiple tobacco product use should be routinely assessed in cancer care settings.
Data from Socioeconomic status at birth and breast tissue composition in adolescence and adulthood
Authors: Kehm Rebecca D. , Lilge Lothar , Walter E Jane , White Melissa , Herbstman Julie B. , Perera Frederica P. , Miller Rachel L. , Terry Mary Beth , Tehranifar Parisa
Published: September 2024

Abstract
Background: Socioeconomic status (SES) at birth is associated with breast cancer risk. Whether this association is driven by changes in breast tissue composition (BTC) prior to adulthood remains unclear.

Methods: We used multivariable linear regression models to examine whether SES at birth is associated with BTC in adolescence and adulthood using data from a New York City cohort of daughters (n=165, 11-20 years) and mothers (n=160, 29-55 years). We used maternal-reported data on daughters’ household income and maternal education at birth, analyzed individually and in combination (SES index). Women also reported their own mothers’ education at birth. We used optical spectroscopy to evaluate BTC measures that positively (water content, collagen content, optical index) and negatively (lipid content) correlate with mammographic breast density, a recognized breast cancer risk factor.

Results: Being in the highest versus lowest category of the SES index was associated with lower lipid content (βadjusted=-0.80, 95% CI=-1.30,-0.31) and higher collagen content (βadjusted=0.54, 95% CI=0.09,0.99) in adolescence. In women with a BMI <30 kg/m2, higher maternal education at birth (≥ vs. < high school degree) was associated with lower lipid content (βadj = -0.57, 95% CI = -0.97,-0.17), higher water content (βadj = 0.70, 95% CI = 0.26,1.14), and higher optical index (βadj = 0.53, 95% CI = 0.10,0.95).

Conclusions: This study supports that SES at birth is associated with BTC in adolescence and adulthood, although the latter association may depend on adult BMI.

Impact: Further research is needed to identify the socially patterned early life factors influencing BTC.
Data from Germline mutations in 12 genes and risk of ovarian cancer in three population-based cohorts
Authors: Kotsopoulos Joanne , Hathaway Cassandra A. , Narod Steven A. , Teras Lauren R. , Patel Alpa V. , Hu Chunling , Yadav Siddhartha , Couch Fergus J. , Tworoger Shelley S.
Published: September 2024

Abstract
Background: With the widespread use of multigene panel genetic testing, population-based studies are necessary to accurately assess penetrance in unselected individuals. We evaluated the prevalence of germline pathogenic or likely pathogenic variants (mutations) in 12 cancer-predisposition genes and associations with ovarian cancer risk in three population-based prospective studies (Nurses’ Health Study [NHS], NHSII, Cancer Prevention Study II).
Methods: We included women with epithelial ovarian or peritoneal cancer (n=776) and controls who were alive and had at least one intact ovary at the time of the matched case diagnosis (n=1,509). Germline DNA was sequenced for mutations in 12 genes. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for ovarian cancer risk by mutation status.
Results: The mutation frequency across all 12 genes was 11.2% in cases and 3.3% in controls (P<0.0001). BRCA1 and BRCA2 were the most frequently mutated (3.5% and 3.8% of cases and 0.3% and 0.5% of controls, respectively) and were associated with increased ovarian cancer risk (OR, BRCA1=12.38; 95%CI=4.72-32.45; OR, BRCA2=9.18; 95%CI=3.98-21.15). Mutation frequencies for the other genes were ≤1.0% and only PALB2 was significantly associated with risk (OR=5.79; 95%CI=1.09-30.83). There was no difference in survival for women with a BRCA germline mutation versus no mutation.
Conclusions: Further research is needed to better understand the role of other mutations in ovarian cancer among unselected populations.
Impact: Our data support guidelines for germline genetic testing for BRCA1 and BRCA2 among women diagnosed with epithelial ovarian cancer; testing for PALB2 may be warranted.
Data from Changes in geographic variation and socioeconomic inequalities in esophageal cancer mortality in China, 1973-2017
Authors: Ran Xianhui , Zheng Rongshou , Zeng Hongmei , Zhang Siwei , Sun Kexin , Han Bingfeng , Wang Shaoming , Chen Ru , Li Li , Wei Wenqiang , He Jie
Published: September 2024

Abstract
Background: Geographic variability in esophageal cancer has been reported in China, but data are lacking at the local level. We aimed to investigate changes in disparities in esophageal cancer mortality among Chinese counties and whether county-level socioeconomic status was associated with this variation.

Methods: We used data from a nationwide survey and population-based cancer registries to calculate esophageal cancer mortality rates for 782 Chinese counties for the periods of 1973-1975 and 2015-2017. We performed hotspot analysis to identify spatial clusters. We used a multivariable negative binomial regression model to estimate the associations between county-level socioeconomic factors and mortality.

Results: From 1973-1975 to 2015-2017, the age-standardized esophageal cancer mortality rate decreased from 27 to 8 per 100,000 person-years in China. By county, 577 (74%) of 782 counties experienced decreasing mortality. Geographic disparities in mortality substantially narrowed, with the gap in mortality rates between 90th and 10th percentile counties decreasing from 55 per 100,000 person-years in 1973-1975 to 16 in 2015-2017. However, clusters of elevated rates persisted across north-central China. Rurality (adjusted mortality rate ratio [MRR] 1.15, 95% CI 1.10-1.21), per capita gross domestic product (adjusted MRR 0.95, 0.91-0.98), and percentage of people with a high school diploma (adjusted MRR 0.86, 0.84-0.87) in a county were significantly associated esophageal cancer mortality rates.

Conclusions: China has made substantial progress in reducing esophageal cancer mortality and disparities, but the intercounty differences remain large.

Impact: Continued efforts are needed to address the geographical and socioeconomic disparities in esophageal cancer.
Data from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Authors: Chen Ji-Qing , Salas Lucas A. , Wiencke John K. , Koestler Devin C. , Molinaro Annette M. , Andrew Angeline S. , Seigne John D. , Karagas Margaret R. , Kelsey Karl T. , Christensen Brock C.
Published: September 2024

Abstract
Background: Immune profiles have been associated with bladder cancer outcomes and may have clinical applications for prognosis. However, associations of detailed immune cell subtypes with patient outcomes remain underexplored and may contribute crucial prognostic information for better managing bladder cancer recurrence and survival.

Methods: Bladder cancer case peripheral blood DNA methylation was measured using the Illumina HumanMethylationEPIC array. Extended cell-type deconvolution quantified twelve immune cell-type proportions, including memory, naïve T and B cells, and granulocyte subtypes. DNA methylation clocks determined biological age. Cox proportional hazard models tested associations of immune cell profiles and age acceleration with bladder cancer outcomes. The partDSA algorithm discriminated 10-year overall survival groups from clinical variables and immune cell profiles, and a semi-supervised recursively partitioned mixture model with DNA methylation data was applied to identify a classifier for 10-year overall survival.

Results: Higher CD8T memory cell proportions were associated with better overall survival (HR=0.95, 95% CI=0.93-0.98), while higher NLR (HR=1.36, 95% CI=1.23-1.50), CD8T naïve (HR=1.21, 95% CI=1.04-1.41), neutrophil (HR=1.04, 95% CI=1.03-1.06) proportions, and age acceleration (HR =1.06, 95% CI=1.03-1.08) were associated with worse overall survival in bladder cancer patients. partDSA and SS-RPMM classified five groups of subjects with significant differences in overall survival.

Conclusions: We identified associations between immune cell subtypes and age acceleration with bladder cancer outcomes.

Impact: The findings of this study suggest that bladder cancer outcomes are associated with specific methylation-derived immune cell-type proportions and age acceleration, and these factors could be potential prognostic biomarkers.
Data from Assessing a Polygenic Risk Score for Lung Cancer Susceptibility in Non-Hispanic White and Black Populations
Authors: Trendowski Matthew R. , Lusk Christine M. , Wenzlaff Angela S. , Neslund-Dudas Christine , Gadgeel Shirish M. , Soubani Ayman O. , Schwartz Ann G.
Published: September 2024

Abstract
Background: Polygenic risk scores (PRS) have become an increasingly popular approach to evaluate cancer susceptibility, but have not adequately represented Black populations in model development.

Methods: We used a previously published lung cancer PRS based on 80 SNPs associated with lung cancer risk in the OncoArray cohort and validated in UK Biobank. The PRS was evaluated for association with lung cancer risk adjusting for age, sex, total pack-years, family history of lung cancer, history of COPD, and the top five principal components for genetic ancestry.

Results: Among the 80 PRS SNPs included in the score, 14 were significantly associated with lung cancer risk (p<0.05) in INHALE White participants, while there were no significant SNPs among INHALE Black participants. After adjusting for covariates, the PRS was significantly associated with risk in Whites (continuous score p=0.007), but not in Blacks (continuous score p=0.88). The PRS remained a statistically significant predictor of lung cancer risk in Whites ineligible for lung cancer screening under current USPSTF guidelines (p=0.02).

Conclusions: Using a previously validated PRS, we did find some predictive ability for lung cancer in INHALE White participants beyond traditional risk factors. However, this effect was not observed in Black participants, indicating the need to develop and validate ancestry-specific lung cancer risk models.

Impact: While a previously published lung cancer PRS was able to stratify White participants into different levels of risk, the model was not predictive in Blacks. Our findings highlight the need to develop and validate ancestry-specific lung cancer risk models.
Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Authors: Chavez Julio C. , Foss Francine M. , William Basem M. , Brammer Jonathan E. , Smith Sonali M. , Prica Anca , Zain Jasmine M. , Tuscano Joseph M. , Shah Harsh , Mehta-Shah Neha , Ramakrishnan Geethakumari Praveen Ramakrishnan. , Wang Ben X. , Zantinge Stephanie , Wang Lisa , Zhang Ling , Boutrin Anmarie , Zhao Weiguang , Cheng Lily , Standifer Nathan , Hewitt Lisa , Enowtambong Enowmpey , Shao Weiping , Sharma Shringi , Carlesso Gianluca , Moscow Jeffrey A. , Siu Lillian L.
Published: September 2024

Supplemental Figure 3. Representative baseline pre-treatment tumor specimen of a patient with AITL (H&E, ICOS staining and CD3 staining by IHC)
Figure S8 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
Authors: McDermott Martina S.J. , O'Brien Neil A. , Hoffstrom Benjamin , Gong KeWei , Lu Ming , Zhang Jun , Luo Tong , Liang Min , Jia Weiping , Hong Jenny , Chau Kevin , Davenport Simon , Xie Bin , Press Michael F. , Panayiotou Richard , Handly-Santana Abram , Brugge Joan S. , Presta Leonard , Glaspy John , Slamon Dennis J.
Published: September 2024

Supplemental Figure S8. A. Layout of tissues and B. Scanned whole-slide image of BN1021, normal human tissue microarray stained for CLDN6 expression showing no staining.
Figure S4 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
Authors: McDermott Martina S.J. , O'Brien Neil A. , Hoffstrom Benjamin , Gong KeWei , Lu Ming , Zhang Jun , Luo Tong , Liang Min , Jia Weiping , Hong Jenny , Chau Kevin , Davenport Simon , Xie Bin , Press Michael F. , Panayiotou Richard , Handly-Santana Abram , Brugge Joan S. , Presta Leonard , Glaspy John , Slamon Dennis J.
Published: September 2024

Supplemental Figure S4: Binding of CLDN6-23-ADC (5 μg/ml) in artificial cell lines overexpressing CLDN3, CLDN4, CLDN6 or CLDN9 by flow cytometry.
Figure S2 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
Authors: McDermott Martina S.J. , O'Brien Neil A. , Hoffstrom Benjamin , Gong KeWei , Lu Ming , Zhang Jun , Luo Tong , Liang Min , Jia Weiping , Hong Jenny , Chau Kevin , Davenport Simon , Xie Bin , Press Michael F. , Panayiotou Richard , Handly-Santana Abram , Brugge Joan S. , Presta Leonard , Glaspy John , Slamon Dennis J.
Published: September 2024

Supplemental Figure S2: Amino acid sequence alignment of CLDN6 (P56747) and CLDN9 (O95484) with the extracellular loops highlighted
Figure S5 from Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
Authors: Bidkar Anil P. , Wang Sinan , Bobba Kondapa Naidu. , Chan Emily , Bidlingmaier Scott , Egusa Emily A. , Peter Robin , Ali Umama , Meher Niranjan , Wadhwa Anju , Dhrona Suchi , Dasari Chandrashekhar , Beckford-Vera Denis , Su Yang , Tang Ryan , Zhang Li , He Jiang , Wilson David M. , Aggarwal Rahul , VanBrocklin Henry F. , Seo Youngho , Chou Jonathan , Liu Bin , Flavell Robert R.
Published: September 2024

Figure S5: Estimated equivalent doses (in Sv) in organs and tumor indicating the highest dose (37 Sv) was delivered to tumor tissue.
Figure S10 from Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
Authors: Bidkar Anil P. , Wang Sinan , Bobba Kondapa Naidu. , Chan Emily , Bidlingmaier Scott , Egusa Emily A. , Peter Robin , Ali Umama , Meher Niranjan , Wadhwa Anju , Dhrona Suchi , Dasari Chandrashekhar , Beckford-Vera Denis , Su Yang , Tang Ryan , Zhang Li , He Jiang , Wilson David M. , Aggarwal Rahul , VanBrocklin Henry F. , Seo Youngho , Chou Jonathan , Liu Bin , Flavell Robert R.
Published: September 2024

Figure S10: Tumor volumes, overall survival, and body weights for the saline and fractionated dose (0.125 µCi x 3) injections in 22Rv1 xenografts. Results show delayed tumor growth and improved survival without the significant toxicity from fractionated dose treatment (n=10).
Figure S5 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Authors: Jang H. Josh , Hostetter Galen , MacFarlane Alexander W. , Madaj Zachary , Ross Eric A. , Hinoue Toshinori , Kulchycki Justin R. , Burgos Ryan S. , Tafseer Mahvish , Alpaugh R. Katherine , Schwebel Candice L. , Kokate Rutika , Geynisman Daniel M. , Zibelman Matthew R. , Ghatalia Pooja , Nichols Peter W. , Chung Woonbok , Madzo Jozef , Hahn Noah M. , Quinn David I. , Issa Jean-Pierre J. , Topper Michael J. , Baylin Stephen B. , Shen Hui , Campbell Kerry S. , Jones Peter A. , Plimack Elizabeth R.
Published: September 2024

Supplementary Figure 5: Overall tumor mutation burden and frequency of mutations in cancer-associated genes in UC tumors.
Figure S4 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Authors: Jang H. Josh , Hostetter Galen , MacFarlane Alexander W. , Madaj Zachary , Ross Eric A. , Hinoue Toshinori , Kulchycki Justin R. , Burgos Ryan S. , Tafseer Mahvish , Alpaugh R. Katherine , Schwebel Candice L. , Kokate Rutika , Geynisman Daniel M. , Zibelman Matthew R. , Ghatalia Pooja , Nichols Peter W. , Chung Woonbok , Madzo Jozef , Hahn Noah M. , Quinn David I. , Issa Jean-Pierre J. , Topper Michael J. , Baylin Stephen B. , Shen Hui , Campbell Kerry S. , Jones Peter A. , Plimack Elizabeth R.
Published: September 2024

Supplementary Figure 4: Weak correlation of TE expression induction with DNA methylation change and viral mimicry activation.
Figure S3 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Authors: Jang H. Josh , Hostetter Galen , MacFarlane Alexander W. , Madaj Zachary , Ross Eric A. , Hinoue Toshinori , Kulchycki Justin R. , Burgos Ryan S. , Tafseer Mahvish , Alpaugh R. Katherine , Schwebel Candice L. , Kokate Rutika , Geynisman Daniel M. , Zibelman Matthew R. , Ghatalia Pooja , Nichols Peter W. , Chung Woonbok , Madzo Jozef , Hahn Noah M. , Quinn David I. , Issa Jean-Pierre J. , Topper Michael J. , Baylin Stephen B. , Shen Hui , Campbell Kerry S. , Jones Peter A. , Plimack Elizabeth R.
Published: September 2024

Supplementary Figure 3: Copy number variation detected by SeSAMe from DNA methylation data.
Supplementary Figure S6 from A tumor suppressive-molecular axis EP300/circRERE/miR-6837-3p/MAVS activates type I interferon pathway and anti-tumor immunity to suppress colorectal cancer
Authors: Ding Nan , You A-Bin , Yang Hu , Hu Guo-sheng , Lai Chun-Ping , Liu Wen , Ye Feng
Published: September 2024

Figure S6: A proposed model of how circRERE functions as a tumor suppressor in CRC.
Supplementary Figure S3 from A tumor suppressive-molecular axis EP300/circRERE/miR-6837-3p/MAVS activates type I interferon pathway and anti-tumor immunity to suppress colorectal cancer
Authors: Ding Nan , You A-Bin , Yang Hu , Hu Guo-sheng , Lai Chun-Ping , Liu Wen , Ye Feng
Published: September 2024

Figure S3: Representative densitometry graphics of Western blot data.
Supplementary Figure S1 from A tumor suppressive-molecular axis EP300/circRERE/miR-6837-3p/MAVS activates type I interferon pathway and anti-tumor immunity to suppress colorectal cancer
Authors: Ding Nan , You A-Bin , Yang Hu , Hu Guo-sheng , Lai Chun-Ping , Liu Wen , Ye Feng
Published: September 2024

Supplementary Figure S1: The parental genes of CircRERE and circPARM1 are lowly expressed in CRC tissues and predict poor prognosis in CRC patients.
Supplementary Figure S2 from Granulocyte colony stimulating factor is a novel mediator of T cell suppression and an immunotherapeutic target for women with colon cancer
Authors: Ray Anita L. , Saunders Apryl S. , Nofchissey Robert A. , Reidy Megan A. , Kamal Maria , Lerner Megan R. , Fung Kar-Ming , Lang Mark L. , Hanson Joshua A. , Guo Shaoxuan , Urdaneta-Perez Maria G. , Lewis Samara E. , Cloyde Michael , Morris Katherine T.
Published: September 2024

Supplementary Figure S2
Supplemental Figure 7 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor
Authors: Rossi Ferdinand , Liu Mengyuan , Tieniber Andrew , Etherington Mark S. , Hanna Andrew , Vitiello Gerardo A. , Param Nesteene J. , Do Kevin , Wang Laura , Antonescu Cristina R. , Zeng Shan , Zhang Jennifer Q. , DeMatteo Ronald P.
Published: September 2024

Supplemental Figure 7.
Supplemental Figure 1 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor
Authors: Rossi Ferdinand , Liu Mengyuan , Tieniber Andrew , Etherington Mark S. , Hanna Andrew , Vitiello Gerardo A. , Param Nesteene J. , Do Kevin , Wang Laura , Antonescu Cristina R. , Zeng Shan , Zhang Jennifer Q. , DeMatteo Ronald P.
Published: September 2024

Supplemental Figure 1.
Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Authors: Liam Chong Kin , Ahmad Azura Rozila , Hsia Te-Chun , Zhou Jianying , Kim Dong-Wan , Soo Ross Andrew. , Cheng Ying , Lu Shun , Shin Sang Won , Yang James Chi-Hsin , Zhang Yiping , Zhao Jun , Berghoff Karin , Bruns Rolf , Johne Andreas , Wu Yi-Long
Published: September 2024

Treatment-related adverse events in treated patients with MET amplification and/or MET IHC 2+/3+
Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Authors: Liam Chong Kin , Ahmad Azura Rozila , Hsia Te-Chun , Zhou Jianying , Kim Dong-Wan , Soo Ross Andrew. , Cheng Ying , Lu Shun , Shin Sang Won , Yang James Chi-Hsin , Zhang Yiping , Zhao Jun , Berghoff Karin , Bruns Rolf , Johne Andreas , Wu Yi-Long
Published: September 2024

Duration of PFS in the patient subgroup with MET amplification
Supplementary Data 3 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
Authors: Kelly Ciara M. , Qin Li-Xuan , Whiting Karissa A. , Richards Allison L. , Avutu Viswatej , Chan Jason E. , Chi Ping , Dickson Mark A. , Gounder Mrinal M. , Keohan Mary Louise. , Movva Sujana , Nacev Benjamin A. , Rosenbaum Evan , Adamson Travis , Singer Samuel , Bartlett Edmund K. , Crago Aimee M. , Yoon Sam S. , Hwang Sinchun , Erinjeri Joseph P. , Antonescu Cristina R. , Tap William D. , D'Angelo Sandra P.
Published: September 2024

Normalized Kynurenine Concentrate Over Time
Supplementary Table S6 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Authors: Rotow Julia , Patel Jyoti D. , Hanley Matthew P. , Yu Helena , Awad Mark , Goldman Jonathan W. , Nechushtan Hovav , Scheffler Matthias , Kuo Chih-Hsi S. , Rajappa Senthil , Harada Guilherme , Clifford Sarah , Santucci Alison , Silva Laura , Tupper Rebecca , Oxnard Geoffrey R. , Kherani Jennifer , Drilon Alexander
Published: September 2024

Dose discontinuation
Supplementary Table S1 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Authors: Rotow Julia , Patel Jyoti D. , Hanley Matthew P. , Yu Helena , Awad Mark , Goldman Jonathan W. , Nechushtan Hovav , Scheffler Matthias , Kuo Chih-Hsi S. , Rajappa Senthil , Harada Guilherme , Clifford Sarah , Santucci Alison , Silva Laura , Tupper Rebecca , Oxnard Geoffrey R. , Kherani Jennifer , Drilon Alexander
Published: September 2024

Enrollment assay
Supplementary Table S3 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Authors: Tolmeijer Sofie H. , Boerrigter Emmy , Sumiyoshi Takayuki , Kwan Edmond M. , Ng Sarah , Annala Matti , Donnellan Grainne , Herberts Cameron , Benoist Guillemette E. , Hamberg Paul , Somford Diederik M. , van Oort Inge M. , Schalken Jack A. , Mehra Niven , van Erp Nielka P. , Wyatt Alexander W.
Published: September 2024

Multivariable Cox proportional hazards models for time to progression and time to death
Supplementary Table S1 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Authors: Tolmeijer Sofie H. , Boerrigter Emmy , Sumiyoshi Takayuki , Kwan Edmond M. , Ng Sarah , Annala Matti , Donnellan Grainne , Herberts Cameron , Benoist Guillemette E. , Hamberg Paul , Somford Diederik M. , van Oort Inge M. , Schalken Jack A. , Mehra Niven , van Erp Nielka P. , Wyatt Alexander W.
Published: September 2024

Representativeness of study participants
Supplementary Figure S8 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Authors: Tolmeijer Sofie H. , Boerrigter Emmy , Sumiyoshi Takayuki , Kwan Edmond M. , Ng Sarah , Annala Matti , Donnellan Grainne , Herberts Cameron , Benoist Guillemette E. , Hamberg Paul , Somford Diederik M. , van Oort Inge M. , Schalken Jack A. , Mehra Niven , van Erp Nielka P. , Wyatt Alexander W.
Published: September 2024

Baseline circulating tumor DNA fraction according to detection status at 4 weeks
Supplementary Figure S6 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Authors: Tolmeijer Sofie H. , Boerrigter Emmy , Sumiyoshi Takayuki , Kwan Edmond M. , Ng Sarah , Annala Matti , Donnellan Grainne , Herberts Cameron , Benoist Guillemette E. , Hamberg Paul , Somford Diederik M. , van Oort Inge M. , Schalken Jack A. , Mehra Niven , van Erp Nielka P. , Wyatt Alexander W.
Published: September 2024

Relationship between on-treatment detection of circulating tumor DNA patient outcomes
Supplementary Figure S5 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Authors: Tolmeijer Sofie H. , Boerrigter Emmy , Sumiyoshi Takayuki , Kwan Edmond M. , Ng Sarah , Annala Matti , Donnellan Grainne , Herberts Cameron , Benoist Guillemette E. , Hamberg Paul , Somford Diederik M. , van Oort Inge M. , Schalken Jack A. , Mehra Niven , van Erp Nielka P. , Wyatt Alexander W.
Published: September 2024

Relationship between baseline circulating tumor DNA fraction and patient outcomes
Supplementary Figure S4 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Authors: Tolmeijer Sofie H. , Boerrigter Emmy , Sumiyoshi Takayuki , Kwan Edmond M. , Ng Sarah , Annala Matti , Donnellan Grainne , Herberts Cameron , Benoist Guillemette E. , Hamberg Paul , Somford Diederik M. , van Oort Inge M. , Schalken Jack A. , Mehra Niven , van Erp Nielka P. , Wyatt Alexander W.
Published: September 2024

Frequency of recurrent somatic alterations compared to published cohorts
Supplementary Table S3 from SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Authors: Kottschade Lisa A. , Pond Gregory Russell. , Olszanski Anthony J. , Zakharia Yousef , Domingo-Musibay Evidio , Hauke Ralph J. , Curti Brendan D. , Schober Sarah , Milhem Mohammed M. , Block Matthew S. , Hieken Tina , McWilliams Robert R.
Published: September 2024

Related Treatment Adverse Events
Supplementary Table S2 from SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Authors: Kottschade Lisa A. , Pond Gregory Russell. , Olszanski Anthony J. , Zakharia Yousef , Domingo-Musibay Evidio , Hauke Ralph J. , Curti Brendan D. , Schober Sarah , Milhem Mohammed M. , Block Matthew S. , Hieken Tina , McWilliams Robert R.
Published: September 2024

Grade 3+ Adverse Events
Table S3 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Authors: Hong David S. , Postow Michael , Chmielowski Bartosz , Sullivan Ryan , Patnaik Amita , Cohen Ezra E.W. , Shapiro Geoffrey , Steuer Conor , Gutierrez Martin , Yeckes-Rodin Heather , Ilaria Robert , O’Connell Brenda , Peng Joanna , Peng Guangbin , Zizlsperger Nora , Tolcher Anthony , Wolchok Jedd D.
Published: September 2024

Summary of anti-tumor activity endpoints in patients treated with eganelisib combination therapy by tumor type
Inclusion and Exclusion Criteria 1 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Authors: Hong David S. , Postow Michael , Chmielowski Bartosz , Sullivan Ryan , Patnaik Amita , Cohen Ezra E.W. , Shapiro Geoffrey , Steuer Conor , Gutierrez Martin , Yeckes-Rodin Heather , Ilaria Robert , O’Connell Brenda , Peng Joanna , Peng Guangbin , Zizlsperger Nora , Tolcher Anthony , Wolchok Jedd D.
Published: September 2024

Study IPI-549-01 full protocol inclusion and exclusion criteria
Supplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial
Authors: Fasching Peter A. , Szeto Christopher , Denkert Carsten , Benz Stephen , Weber Karsten , Spilman Patricia , Budczies Jan , Schneeweiss Andreas , Stickeler Elmar , Schmatloch Sabine , Jackisch Christian , Karn Thomas , Sinn Hans-Peter , Warm Mathias , van Mackelenbergh Marion , Rabizadeh Shahrooz , Schem Christian , Heinmoeller Ernst , Mueller Volkmar , Marme Frederik , Soon-Shiong Patrick , Nekljudova Valentina , Untch Michael , Loibl Sibylle
Published: September 2024

G7 trial design; demographics; tissue types; gene names; displayed data from additional analyses; statistical data
Supplementary Figure S3 from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial
Authors: Joensuu Heikki , Wardelmann Eva , Eriksson Mikael , Reichardt Annette , Sundby Hall Kirsten , Schütte Jochen , Cameron Silke , Hohenberger Peter , Sihto Harri , Jost Philipp J. , Lindner Lars H. , Bauer Sebastian , Nilsson Bengt , Kallio Raija , Pesonen Tommi , Reichardt Peter
Published: September 2024

Kaplan-Meier estimates of recurrence-free survival (A, C, E) and overall survival (B, D, F) of patients with KIT exon 11 insertion or duplication mutation (A, B), patients with PDGFRA exon 18 D842V mutation (C, D), and patients with no detected KIT or PDGFRA mutation (E, F). The 5-year and 10-year survival rates are shown. Censored patients are indicated with a bar.
Supplementary Figure S1 from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial
Authors: Joensuu Heikki , Wardelmann Eva , Eriksson Mikael , Reichardt Annette , Sundby Hall Kirsten , Schütte Jochen , Cameron Silke , Hohenberger Peter , Sihto Harri , Jost Philipp J. , Lindner Lars H. , Bauer Sebastian , Nilsson Bengt , Kallio Raija , Pesonen Tommi , Reichardt Peter
Published: September 2024

Kaplan-Meier estimates of recurrence-free survival (A, C) and overall survival (B, D) of patients with KIT exon 11 deletion mutation (A, B) and patients with KIT exon 11 indel mutation (C, D)
Study Protocol from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial
Authors: Joensuu Heikki , Wardelmann Eva , Eriksson Mikael , Reichardt Annette , Sundby Hall Kirsten , Schütte Jochen , Cameron Silke , Hohenberger Peter , Sihto Harri , Jost Philipp J. , Lindner Lars H. , Bauer Sebastian , Nilsson Bengt , Kallio Raija , Pesonen Tommi , Reichardt Peter
Published: September 2024

Study protocol
Supplementary Table S1 from Collagen-anchored interleukin-2 and interleukin-12 safely reprogram the tumor microenvironment in canine soft tissue sarcomas
Authors: Stinson Jordan A. , Sheen Allison , Momin Noor , Hampel Jordan , Bernstein Rebecca , Kamerer Rebecca , Fadl-Alla Bahaa , Samuelson Jonathan , Fink Elizabeth , Fan Timothy M. , Wittrup K. Dane
Published: September 2024

Protein sequences of canine cytokine fusion proteins
Supplementary Figure S6 from Collagen-anchored interleukin-2 and interleukin-12 safely reprogram the tumor microenvironment in canine soft tissue sarcomas
Authors: Stinson Jordan A. , Sheen Allison , Momin Noor , Hampel Jordan , Bernstein Rebecca , Kamerer Rebecca , Fadl-Alla Bahaa , Samuelson Jonathan , Fink Elizabeth , Fan Timothy M. , Wittrup K. Dane
Published: September 2024

Pathway scores from canine Nanostring nSolver analysis
Supplemental Table 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Authors: Fathi Amir T. , Kim Haesook T. , Soiffer Robert J. , Levis Mark J. , Li Shuli , Kim Annette S. , DeFilipp Zachariah , El-Jawahri Areej , McAfee Steve L. , Brunner Andrew M. , Amrein Philip C. , Mims Alice S. , Knight Laura W. , Kelley Devon , Bottoms AJ S. , Perry Lindsey H. , Wahl Jonathan L. , Brock Jennifer , Breton Elayne , Marchione Dylan M. , Ho Vincent T. , Chen Yi-Bin
Published: September 2024

Representativeness of Study Participants
Supplemental Figure 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Authors: Fathi Amir T. , Kim Haesook T. , Soiffer Robert J. , Levis Mark J. , Li Shuli , Kim Annette S. , DeFilipp Zachariah , El-Jawahri Areej , McAfee Steve L. , Brunner Andrew M. , Amrein Philip C. , Mims Alice S. , Knight Laura W. , Kelley Devon , Bottoms AJ S. , Perry Lindsey H. , Wahl Jonathan L. , Brock Jennifer , Breton Elayne , Marchione Dylan M. , Ho Vincent T. , Chen Yi-Bin
Published: September 2024

Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
Supplementary Tables 1 from Proteostasis modulation in germline missense von Hippel Lindau disease
Authors: Chittiboina Prashant , Mandal Debjani , Bugarini Alejandro , Asuzu David T. , Mullaney Dustin , Mastorakos Panagiotis , Stoica Stefan , Alvarez Reinier , Scott Gretchen , Maric Dragan , Elkahloun Abdel , Zhuang Zhengping , Chew Emily Y. , Yang Chunzhang , Linehan Marston , Lonser Russell R.
Published: September 2024

Supplementary tables in tabs.
Figure S1 from Proteostasis modulation in germline missense von Hippel Lindau disease
Authors: Chittiboina Prashant , Mandal Debjani , Bugarini Alejandro , Asuzu David T. , Mullaney Dustin , Mastorakos Panagiotis , Stoica Stefan , Alvarez Reinier , Scott Gretchen , Maric Dragan , Elkahloun Abdel , Zhuang Zhengping , Chew Emily Y. , Yang Chunzhang , Linehan Marston , Lonser Russell R.
Published: September 2024

Figure S1
Supplementary Table S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Authors: Antoniotti Carlotta , Boccaccino Alessandra , Seitz Robert , Giordano Mirella , Catteau Aurélie , Rossini Daniele , Pietrantonio Filippo , Salvatore Lisa , McGregor Kimberly , Bergamo Francesca , Conca Veronica , Leonetti Simone , Morano Federica , Papiani Giorgio , Tamburini Emiliano , Bensi Maria , Murgioni Sabina , Ross Douglas Teller. , Passardi Alessandro , Boquet Isabelle , Nielsen Tyler J. , Galon Jerome , Varga Matthew Gordon. , Schweitzer Brock L. , Cremolini Chiara
Published: September 2024

Baseline characteristics of patients according to the predefined and optimized DetermaIO score positivity cut-point in the pMMR tumours group.
Supplementary Data 1 from Somatic exonic deletions in RUNX1 constitutes a novel recurrent genomic abnormality in acute myeloid leukemia
Authors: Eriksson Anna , Engvall Marie , Mathot Lucy , Österroos Albin , Rippin Martin , Cavelier Lucia , Ladenvall Claes , Baliakas Panagiotis
Published: September 2024

Supplementary Data
Supplementary Table S2 from Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical implications
Authors: Gouda Mohamed A. , Nelson Blessie Elizabeth. , Buschhorn Lars , Wahida Adam , Subbiah Vivek
Published: September 2024

Frequency of tissue-agnostic targets in other additional different tumors (alphabetically arranged) in AACR GENIE v.13
Supplementary Table S1: Common co-occurring alterations with tissue-agnostic targets in select tumor types from Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical implications
Authors: Gouda Mohamed A. , Nelson Blessie Elizabeth. , Buschhorn Lars , Wahida Adam , Subbiah Vivek
Published: September 2024

Genes most frequently mutated in cases with tissue-agnostic targets in the overall altered population and top 5 cancers with highest number of profiled samples in each alteration
Supplementary Table S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Authors: Tomasich Erwin , Steindl Ariane , Paiato Christina , Hatziioannou Teresa , Kleinberger Markus , Berchtold Luzia , Puhr Rainer , Hainfellner Johannes A. , Müllauer Leonhard , Widhalm Georg , Eckert Franziska , Bartsch Rupert , Heller Gerwin , Preusser Matthias , Berghoff Anna Sophie.
Published: September 2024

Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (HER2+ cohort)
Supplementary Table S2 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Authors: Tomasich Erwin , Steindl Ariane , Paiato Christina , Hatziioannou Teresa , Kleinberger Markus , Berchtold Luzia , Puhr Rainer , Hainfellner Johannes A. , Müllauer Leonhard , Widhalm Georg , Eckert Franziska , Bartsch Rupert , Heller Gerwin , Preusser Matthias , Berghoff Anna Sophie.
Published: September 2024

Baseline characteristics of patients used for genome-wide DNA-methlyation analysis, stratified into HER3-positive and HER3-negative
Supplementary Figure S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Authors: Tomasich Erwin , Steindl Ariane , Paiato Christina , Hatziioannou Teresa , Kleinberger Markus , Berchtold Luzia , Puhr Rainer , Hainfellner Johannes A. , Müllauer Leonhard , Widhalm Georg , Eckert Franziska , Bartsch Rupert , Heller Gerwin , Preusser Matthias , Berghoff Anna Sophie.
Published: September 2024

Further evaluation of HER3 expression in BM of breast and lung cancer.
Table S4 from Clinical importance of the lncRNA NEAT1 in cancer patients treated with immune checkpoint inhibitors.
Authors: Toker Joseph , Iorgulescu J. Bryan. , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: September 2024

Glioblastoma patient characteristics (GSE121810)
Table S1 from Clinical importance of the lncRNA NEAT1 in cancer patients treated with immune checkpoint inhibitors.
Authors: Toker Joseph , Iorgulescu J. Bryan. , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: September 2024

Primers used in the study.
Supplementary Fig. 5 from Clinical importance of the lncRNA NEAT1 in cancer patients treated with immune checkpoint inhibitors.
Authors: Toker Joseph , Iorgulescu J. Bryan. , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: September 2024

Supplementary Fig. 5 Classification of single cells.
Supplementary Fig. 1 from Clinical importance of the lncRNA NEAT1 in cancer patients treated with immune checkpoint inhibitors.
Authors: Toker Joseph , Iorgulescu J. Bryan. , Ling Alexander L. , Villa Genaro R. , Gadet Josephina A.M.A. , Parida Laxmi , Getz Gad , Wu Catherine J. , Reardon David A. , Chiocca E. Antonio , Mineo Marco
Published: September 2024

Supplementary Fig. 1 Analysis of lncRNAs associated with patient response to ICB.
Supplementary Figure S2 from Proinflammatory macrophage activation by the polysialic acid-Siglec-16 axis is linked to increased survival of glioblastoma patients
Authors: Thiesler Hauke , Gretenkort Lina , Hoffmeister Leonie , Albers Iris , Ohlmeier Luisa , Röckle Iris , Verhagen Andrea , Banan Rouzbeh , Köpcke Nora , Krönke Nicole , Feuerhake Friedrich , Behling Felix , Barrantes-Freer Alonso , Mielke Dorothee , Rohde Veit , Hong Bujung , Varki Ajit , Schwabe Kerstin , Krauss Joachim K. , Stadelmann Christine , Hartmann Christian , Hildebrandt Herbert
Published: September 2024

PolySia on CD11c-positive and on CD45-positive, IBA1-negative cells
Supplementary Figure S1 from Proinflammatory macrophage activation by the polysialic acid-Siglec-16 axis is linked to increased survival of glioblastoma patients
Authors: Thiesler Hauke , Gretenkort Lina , Hoffmeister Leonie , Albers Iris , Ohlmeier Luisa , Röckle Iris , Verhagen Andrea , Banan Rouzbeh , Köpcke Nora , Krönke Nicole , Feuerhake Friedrich , Behling Felix , Barrantes-Freer Alonso , Mielke Dorothee , Rohde Veit , Hong Bujung , Varki Ajit , Schwabe Kerstin , Krauss Joachim K. , Stadelmann Christine , Hartmann Christian , Hildebrandt Herbert
Published: September 2024

PolySia is associated with GFAP-positive cells
Supplementary Table S4 from DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy
Authors: Tawk Bouchra , Rein Katrin , Schwager Christian , Knoll Maximilian , Wirkner Ute , Hörner-Rieber Juliane , Liermann Jakob , Kurth Ina , Balermpas Panagiotis , Roedel Claus , Linge Annett , Loeck Steffen , Lohaus Fabian , Tinhofer Ingeborg , Krause Mechthild , Stuschke Martin , Grosu Anca-Ligia , Zips Daniel , Combs Stephanie E. , Belka Claus , Stenzinger Albrecht , Herold-Mende Christel , Baumann Michael , Schirmacher Peter , Debus Jürgen , Abdollahi Amir
Published: September 2024

Supplementary Table S4. Correlations with CIBERSORT immune signature expressions in the TCGA-HNSCC cohort
Supplementary Figures S1 from DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy
Authors: Tawk Bouchra , Rein Katrin , Schwager Christian , Knoll Maximilian , Wirkner Ute , Hörner-Rieber Juliane , Liermann Jakob , Kurth Ina , Balermpas Panagiotis , Roedel Claus , Linge Annett , Loeck Steffen , Lohaus Fabian , Tinhofer Ingeborg , Krause Mechthild , Stuschke Martin , Grosu Anca-Ligia , Zips Daniel , Combs Stephanie E. , Belka Claus , Stenzinger Albrecht , Herold-Mende Christel , Baumann Michael , Schirmacher Peter , Debus Jürgen , Abdollahi Amir
Published: September 2024

Supplementary Figure 1. (Top) Venn Diagram showing the intersect between Hypoxia-M V2 significant DMPs (n=3397) and Hypoxia-M V1 significant DMPs (n=5129) 2551 (66%) of significant DMPs identified based on the 85th percentile of standard deviation are also included in the selection criteria of Hypoxia-M V1. (middle) Hypoxia-M V2 is prognostic in the TCGA HNSCC cohort (p=0.041) and the prognostic effect remained independent on multivariate analysis. (bottom) Multivariate Analysis revealed that patients predicted to have high Hypoxia by Hypoxia-M V2 had worsened OS outcomes (HR=1.59, p<0.026). Additionally, increasing age and pN2 nodal status were negatively prognostic of OS (p<0.05)
Supplementary Figure S4 from DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy
Authors: Tawk Bouchra , Rein Katrin , Schwager Christian , Knoll Maximilian , Wirkner Ute , Hörner-Rieber Juliane , Liermann Jakob , Kurth Ina , Balermpas Panagiotis , Roedel Claus , Linge Annett , Loeck Steffen , Lohaus Fabian , Tinhofer Ingeborg , Krause Mechthild , Stuschke Martin , Grosu Anca-Ligia , Zips Daniel , Combs Stephanie E. , Belka Claus , Stenzinger Albrecht , Herold-Mende Christel , Baumann Michael , Schirmacher Peter , Debus Jürgen , Abdollahi Amir
Published: September 2024

Supplementary Figure 4 (Top). CD8 T cell enrichment is prognostic for Overall Survival (OS),
local recurrence (LR) and disease progression but not for distant metastasis (DM) in HPV
negative HNSCC in the DKTK-ROG cohort (n=88). (Bottom) After adjusting for Immune cell
Infiltration, Hypoxia-M remained an independent prognosticator for local recurrence (HR=3.06,
p<0.01) and for disease progression (HR=2.14, p<0.04) with a trend towards worsened OS
(HR=1.92, p<0.09). CD8-IHC staining was an independent prognosticator for local recurrence
(HR=0.41, p<0.03) an
Supplementary Figure S3 from DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy
Authors: Tawk Bouchra , Rein Katrin , Schwager Christian , Knoll Maximilian , Wirkner Ute , Hörner-Rieber Juliane , Liermann Jakob , Kurth Ina , Balermpas Panagiotis , Roedel Claus , Linge Annett , Loeck Steffen , Lohaus Fabian , Tinhofer Ingeborg , Krause Mechthild , Stuschke Martin , Grosu Anca-Ligia , Zips Daniel , Combs Stephanie E. , Belka Claus , Stenzinger Albrecht , Herold-Mende Christel , Baumann Michael , Schirmacher Peter , Debus Jürgen , Abdollahi Amir
Published: September 2024

Supplementary Figure S3. (Top) Hypoxia-M V2 is associated with decreased OS in the TCGApancancer cohort (p<0.002) (Bottom) Hypoxia-M V2 is an independent prognosticator of OS
(HR=1.81, p<0.03) after adjusting for demographic and clinical factors.
Supplementary Appendix S1 from DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy
Authors: Tawk Bouchra , Rein Katrin , Schwager Christian , Knoll Maximilian , Wirkner Ute , Hörner-Rieber Juliane , Liermann Jakob , Kurth Ina , Balermpas Panagiotis , Roedel Claus , Linge Annett , Loeck Steffen , Lohaus Fabian , Tinhofer Ingeborg , Krause Mechthild , Stuschke Martin , Grosu Anca-Ligia , Zips Daniel , Combs Stephanie E. , Belka Claus , Stenzinger Albrecht , Herold-Mende Christel , Baumann Michael , Schirmacher Peter , Debus Jürgen , Abdollahi Amir
Published: September 2024

Statistical Output
Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Authors: Antonarakis Emmanuel S. , Subudhi Sumit K. , Pieczonka Christopher M. , Karsh Lawrence I. , Quinn David I. , Hafron Jason M. , Wilfehrt Helen M. , Harmon Matthew , Sheikh Nadeem A. , Shore Neal D. , Petrylak Daniel P.
Published: September 2024

Supplementary Fig 2 . Analysis of survival by baseline median alkaline phosphatase across the two studies using the study-specific median.
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Authors: Ailawadhi Sikander , Chen Zi , Huang Bo , Paulus Aneel , Collins Mary C. , Fu Lei (Tommy). , Li Mingyu , Ahmad Mohammad , Men Lichuang , Wang Hengbang , Davids Matthew S. , Liang Eric , Mekala Divya J. , He Zhicong , Lasica Masa , Yannakou Costas K. , Parrondo Ricardo , Glass Laura , Yang Dajun , Chanan-Khan Asher , Zhai Yifan
Published: September 2024

Summary of BH3 profiling for PBMC samples collected at baseline.